Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Valneva (VALN)
NASDAQ:VALN
VALN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.62 - $9.50
Previous CloseN/A
Volume18.63K
Average Volume (3M)58.12K
Market Cap
$387.55M
Enterprise Value$539.83M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.63
Next Earnings
Mar 20, 2025EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding81,260,765
10 Day Avg. Volume45,105
30 Day Avg. Volume58,116
Standard Deviation0.24
R-Squared0.15
Alpha-0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)7.92
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$12.20Price Target Upside117.47% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Valneva News
PremiumCompany Announcements
Valneva’s Chikungunya Vaccine Gains UK Approval, Expanding Global Reach
PremiumCompany Announcements
Valneva Reports Positive Trial Results for Pediatric Chikungunya Vaccine
PremiumCompany Announcements
Valneva’s Chikungunya Vaccine Shows Promising Results in Adolescents
PremiumCompany Announcements
Valneva Engages Investors at J.P. Morgan Healthcare Conference---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceValneva anticipates cash flow positivity for its commercial business, excluding Ixchiq, in 2024 and expects commercial business cash-flow positivity, including Ixchiq, from 2025.
Market Approval And ExpansionThe Advisory Committee on Immunization Practices (ACIP) voted to recommend use of Ixchiq for the prevention of disease caused by CHIKV, and it was adopted by the U.S. CDC.
Strategic FundingThe company announced that it received a grant from the Coalition for Epidemic Preparedness Innovations (CEPI) providing Valneva with up to $41.3M of additional funding over the next five years.
Bears Say
Financial PerformanceIxchiq sales estimate for 2024 is lowered from €4M to €3M.
Market OutlookLowering PT due to slightly lower expectations for Ixchiq sales.
Sales ExpectationsIxchiq sales ramp slower than forecast, impacting overall expectations.
---
Ownership Overview
―
Insiders
0.15%
Mutual Funds
<0.01% Other Institutional Investors
99.85% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
VALN FAQ
What was Valneva’s price range in the past 12 months?
Valneva lowest stock price was $3.62 and its highest was $9.50 in the past 12 months.
What is Valneva’s market cap?
Valneva’s market cap is $387.55M.
When is Valneva’s upcoming earnings report date?
Valneva’s upcoming earnings report date is Mar 20, 2025 which is in 42 days.
How were Valneva’s earnings last quarter?
Valneva released its earnings results on Nov 07, 2024. The company reported -$0.11 earnings per share for the quarter, beating the consensus estimate of -$0.266 by $0.156.
Is Valneva overvalued?
According to Wall Street analysts Valneva’s price is currently Undervalued.
Does Valneva pay dividends?
Valneva does not currently pay dividends.
What is Valneva’s EPS estimate?
Valneva’s EPS estimate is -0.18.
How many shares outstanding does Valneva have?
Valneva has 81,260,765 shares outstanding.
What happened to Valneva’s price movement after its last earnings report?
Valneva reported an EPS of -$0.11 in its last earnings report, beating expectations of -$0.266. Following the earnings report the stock price went down -1.968%.
Which hedge fund is a major shareholder of Valneva?
Currently, no hedge funds are holding shares in VALN
---
Valneva Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$12.20 (117.47% Upside)
$12.20 (117.47% Upside)
Blogger Sentiment
Bullish
VALN Sentiment 100%
Sector Average 71%
Sector Average 71%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 5.7%
Last 30 Days ▼ 5.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-42.55%
12-Months-Change
Fundamentals
Return on Equity
-3.73%
Trailing 12-Months
Asset Growth
4.62%
Trailing 12-Months
Company Description
Valneva
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes two vaccines for travellers; one for the prevention of Japanese encephalitis (IXIARO) and the second (DUKORAL) for the prevention of cholera and diarrhoea. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, and third-party products; Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; and Technologies and services which relates to services and inventions at a commercialization stage. The group is based in France and operates internationally.
---
VALN Company Deck
---
VALN Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
Valneva's earnings call reflects a balanced view with strong product sales growth, a positive financial turnaround, and strategic advancements in R&D. However, challenges persist with the slow uptake of IXCHIQ in the US and increased costs impacting margins. The company is optimistic about future growth prospects and sustained profitability from 2027 onwards.Read More>---
VALN Stock 12 Month Forecast
Average Price Target
$12.20
▲(117.47% Upside)
Technical Analysis
Best Analysts Covering VALN
1 Year
1 Year Success Rate
2/23 ratings generated profit
1 Year Average Return
-27.92%
reiterated a buy rating yesterday
Copying Edward White's trades and holding each position for 1 Year would result in 8.70% of your transactions generating a profit, with an average return of -27.92% per trade.
---